Physician profile
David C Grantham
NPI 1023247244
$10,452.93
in general payments reported to CMS, 2019-2025
19 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2021: $7,938 · 2022: $236 · 2023: $1,073 · 2024: $601 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,937.19 | 2021-2022 | |
| Avita Medical Americas, LLC | $544.54 | 2021-2024 | Recell |
| Smith+Nephew, INC. | $360.93 | 2019-2025 | Oasis, Collagenase Santyl, Acticoat 4" X 4" |
| Polynovo North America LLC | $358.42 | 2022-2025 | Novosorb Btm |
| Vericel Corporation | $352.01 | 2023-2025 | Nexobrid |
| Aroa Biosurgery Incorporated | $316.36 | 2023-2025 | |
| Tela Bio, INC. | $229.99 | 2023-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Integra Lifesciences Corporation | $106.38 | 2023-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Polarityte, INC. | $48.76 | 2019 | |
| Organogenesis INC. | $46.58 | 2023-2024 | Puraply |
| Vertex Pharmaceuticals Incorporated | $24.76 | 2025 | |
| Kerecis Limited | $23.29 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Heron Therapeutics, INC. | $19.91 | 2023 | Zynrelef |
| Kci USA, INC. | $15.86 | 2022 | |
| Medline Industries LP | $15.58 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Osiris Therapeutics INC. | $13.56 | 2019 | |
| Allergan, INC. | $13.22 | 2019 | |
| Melinta Therapeutics, LLC | $13.02 | 2019 | |
| Reprise Biomedical, INC. | $12.57 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.